| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 16,379 | 27,136 | 11,701 | 27,492 |
| Marketable securities | NaN | NaN | 6,971 | NaN |
| Accounts receivable | 5,351 | 5,546 | 387 | 532 |
| Deposits, current portion | 1,062 | 1,093 | 1,747 | 470 |
| Prepaid expenses and other current assets | 1,701 | 1,309 | 3,114 | 2,350 |
| Foreign withholding tax receivable | 1,899 | 1,899 | 1,899 | NaN |
| Total current assets | 26,392 | 36,983 | 25,819 | 30,844 |
| Total property and equipment | 4,025 | 3,904 | 3,904 | NaN |
| Less accumulated depreciation | 3,737 | 3,663 | 3,597 | NaN |
| Property and equipment, net | 288 | 241 | 307 | 454 |
| Operating lease right-of-use asset | 3,318 | 4,074 | 4,602 | 5,118 |
| Foreign withholding tax receivable | NaN | NaN | NaN | 1,899 |
| Deposits | 635 | 666 | 667 | 1,956 |
| Restricted cash | 154 | 154 | 153 | 153 |
| Other long-term assets | 90 | 94 | 96 | 283 |
| Total assets | 30,877 | 42,212 | 31,644 | 40,707 |
| Accounts payable | 3,327 | 3,948 | 2,348 | 3,627 |
| Accrued expenses | 1,499 | 1,611 | 1,871 | 1,518 |
| Current portion of long-term debt, net | NaN | 0 | 1,458 | 2,416 |
| Research and development contract liability, current portion | 0 | 5,335 | 7,816 | 9,579 |
| Operating lease liabilities, current | 1,562 | 1,911 | 2,031 | 2,114 |
| Other current payable | 1,003 | 689 | NaN | NaN |
| Total current liabilities | 7,391 | 13,494 | 15,524 | 19,254 |
| Other long-term payable | NaN | NaN | 190 | 190 |
| Operating lease liabilities, non-current | 1,878 | 2,286 | 2,684 | 3,104 |
| Total liabilities | 9,269 | 15,780 | 18,398 | 22,548 |
| Common stock, 0.001 par value 300,000,000 shares authorized 3,255,359 and 3,220,707 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 3 | 97 | 78 | 76 |
| Additional paid in capital | 395,249 | 394,801 | 383,218 | 380,686 |
| Accumulated other comprehensive loss | NaN | NaN | 1 | NaN |
| Accumulated deficit | -373,644 | -368,466 | -370,051 | -362,603 |
| Total stockholders' equity | 21,608 | 26,432 | 13,246 | 18,159 |
| Total liabilities and stockholders' equity | 30,877 | 42,212 | 31,644 | 40,707 |
Cue Biopharma, Inc. (CUE)
Cue Biopharma, Inc. (CUE)